Mostrar el registro sencillo del ítem

The preclinical discovery and development of opicapone for the treatment of Parkinson’s disease

dc.contributor.authorEttcheto M.
dc.contributor.authorBusquets O.
dc.contributor.authorSánchez-Lopez E.
dc.contributor.authorCano A.
dc.contributor.authorManzine P.R.
dc.contributor.authorVerdaguer E.
dc.contributor.authorOlloquequi J.
dc.contributor.authorAuladell C.
dc.contributor.authorFolch J.
dc.contributor.authorCamins A.
dc.date.accessioned2020-09-02T22:17:21Z
dc.date.available2020-09-02T22:17:21Z
dc.date.issued2020
dc.identifier10.1080/17460441.2020.1767580
dc.identifier.citation15, 9, 993-1004
dc.identifier.issn17460441
dc.identifier.urihttps://hdl.handle.net/20.500.12728/4408
dc.descriptionIntroduction: Opicapone (OPC) is a well-established catechol-O-methyltransferase (COMT) inhibitor that is approved for the treatment of Parkinson’s disease (PD) associated with L-DOPA/L-amino acid decarboxylase inhibitor (DDI) therapy allowing for prolonged activity due to a more continuous supply of L-DOPA in the brain. Thus, OPC decreases fluctuation in L-DOPA plasma levels and favors more constant central dopaminergic receptor stimulation, thus improving PD symptomatology. Areas covered: This review evaluates the preclinical development, pharmacology, pharmacokinetics and safety profile of OPC. Data was extracted from published preclinical and clinical studies published on PUBMED and SCOPUS (Search period: 2000–2019). Clinical and post-marketing data are also evaluated. Expert opinion: OPC is a third generation COMT inhibitor with a novel structure. It has an efficacy and tolerability superior to its predecessors, tolcapone (TOL) and entacapone (ENT). It also provides a safe and simplified drug regimen that allows neurologists to individually adjust the existing daily administration of L-DOPA. OPC is indicated as an adjunctive therapy to L-DOPA/DDI in patients with PD and end-of-dose motor fluctuations who cannot be stabilized on those combinations. © 2020 Informa UK Limited, trading as Taylor & Francis Group.
dc.language.isoen
dc.publisherTaylor and Francis Ltd
dc.subjectdyskinesia
dc.subjectentacapone
dc.subjectOpicapone
dc.subjectParkinson’s disease
dc.subjecttolcapone
dc.subjectopicapone
dc.subjectArticle
dc.subjectcardiotoxicity
dc.subjectclinical study
dc.subjectconstipation
dc.subjectdizziness
dc.subjectdrug approval
dc.subjectdrug efficacy
dc.subjectdrug half life
dc.subjectdrug marketing
dc.subjectdrug mechanism
dc.subjectdrug research
dc.subjectdrug safety
dc.subjectdrug tolerability
dc.subjectdyskinesia
dc.subjectevaluation study
dc.subjecthuman
dc.subjectinsomnia
dc.subjectliver toxicity
dc.subjectmaximum concentration
dc.subjectmotor performance
dc.subjectnonhuman
dc.subjectParkinson disease
dc.subjectpharmacokinetic parameters
dc.subjectpharmacological parameters
dc.subjectpreclinical study
dc.subjectpriority journal
dc.subjectside effect
dc.subjectsystematic review
dc.subjectxerostomia
dc.titleThe preclinical discovery and development of opicapone for the treatment of Parkinson’s disease
dc.typeArticle


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-85086026359.pdf
Tamaño:
3.384Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem